# Temple University Gastroparesis Clinical Center

> **NIH NIH U01** · TEMPLE UNIV OF THE COMMONWEALTH · 2020 · $368,794

## Abstract

PROJECT SUMMARY
Patients with gastroparesis often suffer with chronic gastrointestinal symptoms that are not adequately treated
due to both a lack of understanding of the underlying pathophysiology and lack of effective treatments. The
participation of Temple University as a clinical center in the NIDDK Gastroparesis Clinical Research
Consortium and the proposed studies will help achieve the broad, long term objectives of improving the
understanding and treatment of patients with gastroparesis. The PI and Temple University are well qualified to
continue to be one of the clinical centers in this consortium. Temple University has clinical expertise and an
active research program in the evaluation and treatment of patients with gastroparesis. The aims for this
renewal of the Gastroparesis Consortium are threefold. First, to better understand the pathologic basis of
gastroparesis by continuing to provide gastric full thickness biopsy specimens from patients with gastroparesis.
We are now collecting specimens from the antrum and obtaining freshly frozen tissue for RNA expression.
Second, to better understand the clinical manifestations and pathophysiology of patients with symptoms of
gastroparesis by maintaining and expanding the Gastroparesis Registry. Our goal is to have four years of
follow-up on patients which will require maintenance of the Registry and continued periodic follow-up visits.
We propose to continue recruitment of new patients. Refinements to existing questionnaires and
pathophysiologic measures, as well as new ones, will allow us to answer questions related to the
pathogenesis, severity grading, complications, treatment responses, and clinical outcomes in patients with
gastroparesis. Third, to conduct new multicenter studies of gastroparesis investigating the pathophysiology,
diagnosis, and treatment. Our application proposes three studies, each aimed at the understanding of the
pathophysiology of symptoms and treatment of symptoms from gastroparesis. Improved testing will better
associate pathophysiology with gastroparesis symptoms and ultimately enable targeted therapy to the
underlying gastric pathophysiologic abnormality. Our first study will determine the effect of the 5HT-1 receptor
agonist, buspirone, on early satiety and intragastric meal distribution in patients with symptoms of
gastroparesis. Our second study is an evaluation of abdominal pain in gastroparesis, determining the
prevalence of and response to treatment for chronic pancreatitis. Finally, our third study will assess the clinical
outcome of patients undergoing endoscopic pyloromyotomy for gastroparesis, looking at the response and
predictive factors for clinical improvement with this novel treatment. These three studies will ultimately enable
physicians to better target therapy to the underlying pathophysiologic abnormalities in patients with
gastroparesis. Temple's participation in the NIH Gastroparesis Clinical Consortium and the undertaking of
Temple's propos...

## Key facts

- **NIH application ID:** 10001061
- **Project number:** 5U01DK073975-15
- **Recipient organization:** TEMPLE UNIV OF THE COMMONWEALTH
- **Principal Investigator:** HENRY PAUL PARKMAN
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $368,794
- **Award type:** 5
- **Project period:** 2006-04-15 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10001061

## Citation

> US National Institutes of Health, RePORTER application 10001061, Temple University Gastroparesis Clinical Center (5U01DK073975-15). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10001061. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*